In the press2017-10-02T16:20:11+02:00

In the press

Redbiotec is a privately held biopharmaceutical company located in Zurich-Schlieren, Switzerland. Redbiotec develops immunotherapies against Herpes and cancer.

We are happy to keep you informed about the latest developments. To subscribe to our newsletter, please send an email to newsletter@redbiotec.ch.

1501, 2015

Global media coverage “Pfizer acquires Redvax GmbH, a spin-off from Redbiotec”

January 15th, 2015|

We are pleased with the global media coverage of the acquisition of our spin-off company Redvax GmbH by Pfizer Inc.. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

Coverage of “Pfizer-Redvax deal” by selected media:

Pfizer Inc.